DRIO — Q2 2026 Financial Report Analysis

DarioHealth (Nasdaq: DRIO) sells digital programs for chronic conditions such as diabetes, high blood pressure, weight, back pain and mental health. Each program pairs an FDA-cleared connected device (a glucose meter or blood-pressure cuff) with an app and coaching. It sells two ways: to employers, health plans and drug makers, who pay for the people they cover, and directly to consumers. In the second quarter of 2026 (April–June), revenue slipped 3.6% to $5.18 million. The net loss narrowed 39% to $7.92 million, mostly because operating costs fell 20% after post-merger job cuts. Under the headline, the business-customer side shrank 29% while consumer hardware sales grew. Part of the gross-margin gain came from a one-time tariff refund. The company ended June with about $14 million in cash and deposits, then raised $22.8 million net in July.

The quarter in numbers

For the first half, revenue was $10.76M (-11.2%) and the net loss was $16.17M (-27.2%). Revenue also fell from the first quarter: Q1 2026 revenue works out to $5.58M, so Q2 was about 7% lower.

Where revenue went

The company describes itself as mainly a B2B business, with employers, health plans and pharma as "three-fourths of our current revenues". This quarter's figures don't support that. B2B2C revenue (programs paid for by an employer, insurer or drug maker on behalf of its people) was $2.50M, down from $3.54M. Consumer revenue (people buying devices and memberships themselves) was $2.67M, up from $1.83M. The 10-Q blames the drop mainly on "non-recurring revenue from a pharmaceutical partner recognized in the prior-year period". Growth from channel partners and higher direct-to-consumer sales partly offset it.

That mix matters for the margin. Services revenue, mostly software and coaching, cost $440K to deliver against $2.59M of sales, a gross margin of about 83%. Consumer hardware cost $1.37M against $2.59M of sales, about 47%. Every dollar that shifts from services to hardware lowers profitability per dollar, even when total revenue holds steady.

Where the savings came from

Operating expenses fell $2.49M year on year:

• Research and development: $2.10M, down 43.6%. The 10-Q credits "efficiencies resulting from post-merger integration activities, and the utilization of AI, resulting in a decrease in headcount and payroll expenses". The 2025 Twill acquisition is still being folded in.
• General and administrative: $2.60M, down 19.1%. The causes were lower stock-based pay, lower public-company costs and lower legal and accounting fees.
• Sales and marketing: $4.97M, down only 5%. Lower payroll was offset by more digital marketing spend, the kind that drives consumer sales. Sales and marketing alone was 96% of revenue.

Below the operating line, financial expenses fell from $3.79M to $1.12M. Last year's figure included a one-time revaluation charge on the then-new Callodine loan. This year's is mostly ongoing interest ($1.12M a quarter) on a $31.1M term loan that pays SOFR plus 7.75%.

Takeaway: Nearly all of the 39% smaller loss came from cutting costs, not from growth. Revenue shrank, the business-customer side fell 29%, and the underlying gross margin went down once a one-time tariff refund is removed. The cost cuts bought time. The July raise bought more. Whether DarioHealth can start growing revenue again depends on the new employer and health-plan contracts going live in late 2026.

What the headline numbers hide

• The gross-margin jump is flattered by a one-off. After the U.S. Supreme Court struck down the IEEPA tariffs in February 2026, the company booked a $369K tariff-refund benefit in cost of revenues in the first half. Of that, $265K relates to costs paid in prior years. The MD&A says the benefit was recorded in the three months ended June 30. If all of it fell in Q2, gross margin without it was about 54.5%, slightly below last year's 55.2%. Lower amortization of acquired technology also helped ($178K vs $433K), which is an accounting cost rolling off, not an operating improvement. The company's own "adjusted" gross margin (65.2% vs 63.6%) excludes amortization but keeps the tariff refund. Without the refund it would be about 58.0%, down from 63.6%. The mix shift toward hardware is pulling the underlying margin down. Only about $23K of the $536K total refund had been received in cash by the filing date.
• The per-share improvement overstates the change. The loss per share fell 76%, from $3.54 to $0.85, but last year's figure used the "two-class" method. Under that method $9.78M of the prior-year loss was allocated to holders of preferred stock that has since converted to common. Meanwhile the weighted share count rose from 2.48M to 9.34M (adjusted for the 1-for-20 reverse split in August 2025). The July offering adds another ~3.45M shares including pre-funded warrants, about 37% more on top of that. Existing shareholders own a shrinking slice of a company whose total loss is still about $8M a quarter.
• Cash burn is lower than the net loss, but still heavy. Operations used $12.1M in the first half against a $16.2M net loss. The gap is mostly non-cash charges such as stock-based pay ($2.07M) and amortization ($0.93M). Cash burn fell only 4.7% from the prior-year half ($12.7M), much less than the 27% drop in net loss. Financing brought in nothing net in the half: the at-the-market share sales raised $104K, about what they cost.
• The lender's cash floor was close. A November 2025 loan amendment requires at least $10M of unencumbered liquid assets. At June 30, cash plus short-term deposits were about $14.0M, roughly 2 months of burn above that floor. The July raise moved the balance well clear of it. Loan principal repayments start in May 2028.
• A one-off tax charge of $328K, a prior-year provision at the Indian subsidiary, made the net loss slightly worse this quarter.
• Leadership turnover: President and Chief Commercial Officer Steven Nelson's medical leave was extended indefinitely on July 10. He signed a separation agreement on August 20 (8-K filings), and a director retired on September 2. Nelson led the B2B sales push that the outlook depends on.

Outlook

The 10-Q gives no revenue or loss guidance. Management's forward statements are about contracts and cash. A Fortune 50 employer chose Dario's cardiometabolic program for more than 100,000 eligible employees, with launch "expected in the second half of 2026". A top-five U.S. health insurer expanded its contract to add hypertension care. The company also launched an integrated GLP-1 (weight-loss drug) program through licensed providers. On liquidity, management says the July offering ($23.5M gross at $6.80 a share, $22.8M net), plus cash on hand, covers obligations for at least 12 months. It also warns resources "may be consumed more rapidly than currently anticipated".

Our read: on a rough pro-forma basis, the June balance ($14.0M) plus the July raise ($22.8M) is about $37M. At the first half's operating burn of about $24M a year, that is roughly a year and a half of runway before any revenue growth, and before the $10M covenant floor eats into it. That is longer than the 12 months management certifies, but not comfortable. The next two quarters should show whether the Fortune 50 launch and the insurer expansion turn B2B2C revenue back up. If Q3 and Q4 still show B2B2C shrinking while consumer hardware carries the top line, gross margin will keep drifting down. In that case the cost-cutting story runs out before the growth story starts. Watch B2B2C revenue, gross margin without the tariff refund, and quarterly operating cash burn against roughly $6M a quarter.